Welcome to our dedicated page for Frequency Electr SEC filings (Ticker: FEIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Frequency Electronics Inc.’s satellite and defense contracts across hundreds of pages can drain hours. Specifications on rubidium oscillators, classified backlog shifts, and segment margins are sprinkled through each document, making even seasoned analysts hunt for answers.
Stock Titan’s AI solves that problem. Our platform ingests every Frequency Electronics SEC filing the moment it hits EDGAR and creates plain-language digests so you can move from data to decision fast. Whether you need the latest Frequency Electronics quarterly earnings report 10-Q filing, an alert on Frequency Electronics Form 4 insider transactions real-time, or a deep dive into an 8-K material event, we surface what matters and annotate it with contextual benchmarks.
Inside this page you’ll find:
- 10-K & 10-Q clarity: Revenue by FEI-NY vs. FEI-Zyfer, R&D spend, and satellite backlog�Frequency Electronics annual report 10-K simplified for quick ratio checks.
- Form 4 insight: Understand Frequency Electronics insider trading Form 4 transactions and monitor executive stock transactions Form 4 before market moves.
- Proxy transparency: View the latest Frequency Electronics proxy statement executive compensation without wading through boilerplate.
- 8-K radar: Get Frequency Electronics 8-K material events explained when new government awards or supply-chain updates hit.
Each document comes with AI-powered summaries, key-term search, and comparative charts so understanding Frequency Electronics SEC documents with AI feels effortless. Save time, catch critical details, and rely on our Frequency Electronics earnings report filing analysis to stay ahead.
Dare Bioscience, Inc. (DARE) filed a Form 4 disclosing the grant of 4,500 non-qualified stock options to independent director Jessica D. Grossman on 07/09/2025. The options carry an exercise price of $2.44 per share and expire on 07/09/2035.
Vesting terms: The award vests in full on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the company’s first annual shareholder meeting following the grant. Full acceleration occurs upon a change in control, provided the director remains on the board.
Post-grant holdings: Following this transaction, Dr. Grossman beneficially owns 4,500 derivative securities (stock options) and no change was reported for common shares in Table I, indicating the grant is additive rather than a sale.
Governance context: Routine equity compensation for directors aligns incentives with shareholder interests but results in a modest potential dilution of approximately 0.01% of outstanding shares, assuming ~45 million shares outstanding (company total not provided in filing). No cash was exchanged and there is no immediate earnings impact.